Central Lombok, NTB (ANTARA) - Indonesian Vice President Ma'ruf Amin stated that the government will continue to investigate the causes of acute kidney failure in children.

"We have urged the Ministry of Health and the Food and Drug Supervisory Agency (BPOM) to supervise and control the cause of this acute kidney failure," Amin noted in Central Lombok, West Nusa Tenggara (NTB), on Friday.

Earlier, a confirmed case came to light of a one-year-old child, who died of Atypical Progressive Acute Kidney Disorder (GGAPA) in Jakarta in early February of 2023.

It all started when the patient developed fever on January 25, 2023, and was given a fever-reducing syrup drug purchased at a pharmacy under the Praxion brand.

After consuming the syrup drug, the patient started experiencing cough, fever, and runny nose and was unable to urinate, a condition called anuria, and was then taken to the Pasar Rebo Health Center, Jakarta, for an examination. Three days later, the patient was referred to Adhyaksa Hospital.

Since the health authority found symptoms of GGAPA, the hospital decided to refer the patient to Cipto Mangunkusmo Hospital (RSCM), but the family refused and requested to go home.

On February 1, 2023, the parents brought the patient to the National Police Hospital and received treatment in the emergency room.

At the same time, the patient was then referred to the RSCM for intensive care as well as for fomepizole therapy, but three hours later, the patient was declared dead at 23:00 local time.

"We also ask the Ministry of Health to assist the other affected patients. We must continue to investigate the root cause of this disease," Amin remarked.

The BPOM has also announced that Praxion syrup is safe for consumption based on a series of tests.

However, the BPOM has ordered the temporary suspension of the production and distribution of drugs consumed by the patient, who was confirmed to have succumbed to GGAPA.

PT Pharos Indonesia, as the manufacturer, also voluntarily recalled Praxion syrup products from the related batch, as the responsibility of the pharmaceutical industry.

To ensure product quality and safety, PT Pharos Indonesia also conducts inspections at three accredited external laboratories. The results of this examination will be available in the next few days.

Related news: IDAI asks pediatricians not to prescribe Praxion syrup
Related news: Jakarta recommends non-drug therapy to prevent acute kidney disease
Related news: Acute kidney failure: Police put two suspects on DPO list

Translator: Desca Lidya N, Resinta S
Editor: Azis Kurmala
Copyright © ANTARA 2023